VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
2 hedge funds and large institutions have $339K invested in VALEANT PHARMACEUTICALS INTL in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
38,782% more capital invested
Capital invested by funds: $871 → $339K (+$338K)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBI
Baxter Bros Inc
Riverside,
Connecticut
|
+$338K |
Top Sellers
VRX Hedge Fund Activity: Q1 2017 in Review
2 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q1 2017, worth a combined $339K — up 38,782% from $871 a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new VRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baxter Bros Inc, opening a new position worth an estimated $338K.
- 2 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q1 2017, up from 1 in Q4 2016.
- Funds reported $339K of VALEANT PHARMACEUTICALS INTL stock for Q1 2017, up 38,782% quarter-over-quarter.
- 1 fund opened new VALEANT PHARMACEUTICALS INTL positions in Q1 2017 and 0 closed out, a net change of +1 holder.
- The largest VALEANT PHARMACEUTICALS INTL buyer in Q1 2017 was Baxter Bros Inc, an estimated $338K added.
Based on aggregated 13F filings for Q1 2017.